Drug company to pay $95M to settle allegations of improper promotions for three drugs

Oct 29 2012NewsGuard 100/100 Score

The Associated Press/Washington Post: Pharmaceutical Company to Pay $95M To Settle Allegations Of Improper Drug Promotion
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday. The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis (10/25).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

First-generation antihistamine drugs could increase seizure risk among young children
Cardiovascular risks of COVID-19 antivirals
TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies
Air pollution spikes drive unnecessary antibiotic use, fueling resistance
Triptans better at relieving migraine pain than recently marketed and more expensive drugs
New insights into stiff-person syndrome, advancing diagnosis and treatment
Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing
Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials